AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

October 8, 2021 Auto Bot AbbVie, approval, Atopic Dermatitis, Health Canada, regulatory, Rinvoq, Upadacitinib 0

Shots:

  • The approval is based on the P-III clinical trial program including Measure Up 1/2/AD Up that evaluates the efficacy & safety of Rinvoq (15/30 mg, qd) as monothx. with TCS vs PBO in 2500+ adults & adolescents with AD
  • In all three studies, the co-primary EPs showed 75% improvement in EASI 75 and vIGA-AD score of 0/1 (clear or almost clear) @16wks. The therapy demonstrated improvements in skin clearance and itch reduction
  • Rinvoq is a JAK inhibitor that is used to treat adults and adolescents aged ≥12yrs. with AD who are not adequately controlled with a systemic treatment or when the use of the therapies is inadvisable

Click here to­ read full press release/ article | Ref: Abbvie | Image: Pharma Live

The post AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis first appeared on PharmaShots.